Short Summary
Ascentcare Dental Products petitions the PTAB to invalidate 18 claims of Solmetex’s 2023 intraoral mesh patent, asserting anticipation and obviousness over five earlier dental mouthpiece references. The petition seeks institution of an IPR and cancellation of the challenged claims.
Detailed Summary
In a petition filed on May 20, 2025, Ascentcare Dental Products, Inc. challenges U.S. Patent No. 11,589,969, titled “Intraoral Device with Mesh,” owned by Solmetex, LLC. The petitioner alleges that claims 1‑4 and 6‑19 are unpatentable, citing anticipation under 35 U.S.C. § 102(b) and obviousness under 35 U.S.C. § 103 based on prior‑art references Black, Park, Baughan, Johnson, and Hirsch. Detailed grounds map each claim limitation to the cited references, arguing that the patent owner broadened claim scope after the petitioner’s product launch, rendering the claims obvious or anticipated. The petition requests that the PTAB institute an inter‑partes review and cancel the challenged claims.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Ascentcare Dental Products, Inc. vs Solmetex, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Samsung Electronics Co. Ltd. et al.vsMaxell, LTD.
The Board granted institution for IPR2025-01311, allowing the challenge to proceed to merits review after determining the petitioner met the required likelihood of success standard.
Samsung Electronics Co., Ltd. et al.vsHeadwater Research LLC
Samsung has filed a rehearing request challenging the USPTO’s denial of institution for its IPR on the grounds that the agency’s retroactive policy change violated due process, the APA, and statutory limits. The petition seeks reinstatement of the Board’s original institution decision.
Sandisk Technologies, Inc. et al.vsLongitude Flash Memory Solutions Ltd. et al.
SanDisk and Longitude settled their IPRs over flash‑memory patents before trial, leading the Board to dismiss the petitions and terminate the proceedings.
Berkshire Hathaway Energy Company et al.vsMES, Inc.
Berkshire Hathaway Energy’s subsidiaries and patent owner Birchtech have settled their dispute over U.S. Patent 10,343,114. The parties filed a joint motion to terminate the inter partes review concerning WEC Energy Group, citing settlement and statutory provisions.
Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.
Merck defends its PH20 enzyme patent in a PTAB Director Review proceeding, arguing that the claims satisfy §112 written description and enablement and that Halozyme's claim‑construction objections are unfounded. The petitioner also contends that Fintiv factors do not justify discretionary denial.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.